Jacobson Center for Clinical & Translational Research

Main Menu


Additional Information


Contact Us

Multiple Sclerosis Research

Study Title:  Long-Term, Prospective, Multinational, Parallel-Cohort Study Monitoring Safety in Patients with MS Newly Started with Fingolimod Once Daily or Treated with Another Approved Disease-Modifying Therapy (PASSAGE).  (Identifier: NCT01442194)

Study Purpose:  The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety safety profile of fingolimod under conditions of routine medical practice.

Principal Investigator: Vicki Ramsey-Williams,, MD

Study Coordinator:  For more information email Andrea Korsnack, RN or call 419-383-3801.

Study Title:  A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy ad Safety of Ofatumumab versus Teriflunomide in Patients with Relapsing Multiple Sclerosis (COMB157G2302)  (Identifier: NCT02792231)

Study Purpose:  To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis.

Principal Investigator: Boyd Koffman, MD

Study Coordinator:  For more information email Andrea Korsnack, RN or call 419-383-3801.


Last Updated: 9/12/17